Literature DB >> 3356752

Spontaneous fusion between metastatic mammary tumor subpopulations.

F R Miller1, D McInerney, C Rogers, B E Miller.   

Abstract

This study describes a differential frequency of spontaneous fusion between metastatic and nonmetastatic subpopulations derived from a single mouse mammary tumor. Subpopulations 66, 66c14 (a variant of 66 which is resistant to both thioguanine and ouabain), 410.4, and 44FTO (a thioguanine-resistant, ouabain-resistant derivative of 410.4) spontaneously metastasize from subcutaneous and mammary fatpad sites. Subpopulations 168, 168FARO (a diaminopurine-resistant, ouabain-resistant derivative of 168), 67, 68H, and 410 do not. The ability of these subpopulation lines to fuse spontaneously in vitro was determined after coculturing a drug-resistant line with a wild-type line in nonselective media. After 16-20 h of coculture, cells were plated in the appropriate media to select for fusion products--either HAT (hypoxanthine, aminopterin, thymidine) plus ouabain or AA (alanosine, adenine) plus ouabain--to determine the number of colony-forming cells (fusion products) present per 10(4) cells plated. When both subpopulations of the pair in the fusion mixture were metastatic, a significantly greater number of fusion products was recovered than if one or both of the subpopulations in the fusion mixture was nonmetastatic, with one exception: line 410 readily fused with both 66c14 and 44FTO. Subline 410 was highly metastatic when originally isolated but lost its metastatic competence after a brief time in tissue culture.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3356752     DOI: 10.1002/jcb.240360204

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  25 in total

Review 1.  Cell fusion as a hidden force in tumor progression.

Authors:  Xin Lu; Yibin Kang
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

Review 2.  Cellular interactions in metastasis.

Authors:  F R Miller; G H Heppner
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

3.  Melanoma x macrophage hybrids with enhanced metastatic potential.

Authors:  M Rachkovsky; S Sodi; A Chakraborty; Y Avissar; J Bolognia; J M McNiff; J Platt; D Bermudes; J Pawelek
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

4.  Fusion between cancer cells and myofibroblasts is involved in osteosarcoma.

Authors:  Ling Yu; Weichun Guo; Shenghao Zhao; Fuan Wang; Yong Xu
Journal:  Oncol Lett       Date:  2011-07-14       Impact factor: 2.967

Review 5.  Perspectives on the mesenchymal origin of metastatic cancer.

Authors:  Leanne C Huysentruyt; Thomas N Seyfried
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

Review 6.  Breast tumor microenvironment: proteomics highlights the treatments targeting secretome.

Authors:  Shui-Tein Chen; Tai-Long Pan; Hsueh-Fen Juan; Tai-Yuan Chen; Yih-Shyan Lin; Chun-Ming Huang
Journal:  J Proteome Res       Date:  2008-02-22       Impact factor: 4.466

7.  Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants.

Authors:  Xin Lu; Yibin Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-20       Impact factor: 11.205

8.  Phenotypic drug profiling in droplet microfluidics for better targeting of drug-resistant tumors.

Authors:  S Sarkar; N Cohen; P Sabhachandani; T Konry
Journal:  Lab Chip       Date:  2015-12-07       Impact factor: 6.799

9.  Efficiency of communication between tumour cells in collagen gel cultures.

Authors:  F R Miller; D McEachern; B E Miller
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

10.  Fusion of CCL21 non-migratory active breast epithelial and breast cancer cells give rise to CCL21 migratory active tumor hybrid cell lines.

Authors:  Benjamin Berndt; Sonja Haverkampf; Georg Reith; Silvia Keil; Bernd Niggemann; Kurt S Zänker; Thomas Dittmar
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.